Crystals of Na+/K+-ATPase with bound cisplatin

Biochemical Pharmacology

Volumn 92, Issue 3, 2014, Pages 494-498

  Huliciak, Miroslav ^a,b,c   Reinhard, Linda ^b,c,d,e   Laursen, Mette ^b,c,e   Fedosova, Natalya ^b,c   Nissen, Poul ^b,c   Kubala, Martin ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b AARHUS UNIVERSITY   (Denmark)

^c DANISH NATIONAL RESEARCH FOUNDATION   (Denmark)

^d KAROLINSKA INSTITUTE   (Sweden)

^e DESY   (Germany)

Author keywords

Adverse effects; Binding sites; Cisplatin; Na+ k+ atpase; Sodium pump; X ray crystallography

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CATION; CISPLATIN; OUABAIN; METHIONINE;

ARTICLE; BINDING SITE; CATALYSIS; CATION TRANSPORT; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTALLIZATION; CRYSTALLOGRAPHY; CYTOPLASM; DRUG MECHANISM; ION EXCHANGE; PROTEIN PURIFICATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

CISPLATIN; CRYSTALLOGRAPHY, X-RAY; METHIONINE; MODELS, MOLECULAR; OUABAIN; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84910595727     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.08.029     Document Type: Article

References (34)

1. Miller RP, Tadagavadi RK, Ramesh GWBR. Mechanisms of cisplatin nephrotoxicity. Toxins 2010;2:2490-518.
2. Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 2008;6:1-18.
3. Dzagnidze A, Katsarava Z, Makhalova J, Liedert B, Yoon MS, Kaube H, et al. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci 2007;27:9451-7.
4. Ries F, Klastersky J. Nephrotoxicity induced by cancer-chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 1986;8:368-79.
5. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008;73:994-1007.
6. Jorgensen PL, Hakansson KO, Karlish SJD. Structure and mechanism of Na/K-ATPase: functional sites and their interactions. Annu Rev Physiol 2003;65:817-49.
7. Morth JP, Pedersen BP, Toustrup-Jensen MS, Sorensen TLM, Petersen J, Andersen JP, et al. Crystal structure of the sodium-potassium pump. Nature 2007;450. 1043-U6.
8. Shinoda T, Ogawa H, Cornelius F, Toyoshima C. Crystal structure of the sodium-potassium pump at 2.4 angstrom resolution. Nature 2009;459. 446-U167.
9. Nyblom M, Poulsen H, Gourdon P, Reinhard L, Andersson M, Lindahl E, et al. Crystal structure of Na+, K+-ATPase in the Na+-bound state. Science 2013;342:123-7.
10. Kanai R, Ogawa H, Vilsen B, Cornelius F, Toyoshima C. Crystal structure of a Na+-bound Na+,K+-ATPase preceding the E1P state. Nature 2013;502:201-6.
11. Laursen M, Yatime L, Nissen P, Fedosova NU. Crystal structure of the high-affinity Na+,K+-ATPase-ouabain complex with Mg2+ bound in the cation binding site. Proc Natl Acad Sci U S A 2013;110:10958-63.
12. Geering K. The functional role of beta subunits in oligomeric P-type ATPases. J Bioenerg Biomembr 2001;33:425-38.
13. Takeuchi A, Reyes N, Artigas P, Gadsby DC. The ion pathway through the opened Na(+),K(+)-ATPase pump. Nature 2008;456:413-6.
14. Poulsen H, Khandelia H, Morth JP, Bublitz M, Mouritsen OG, Egebjerg J, et al. Neurological disease mutations compromise a C-terminal ion pathway in the Na+/K+-ATPase. Nature 2010;467:99-102.
15. Olesen C, Picard M, Winther AML, Gyrup C, Morth JP, Oxvig C, et al. The structural basis of calcium transport by the calcium pump. Nature 2007;450. 1036-U5.
16. Yatime L, Laursen M, Morth JP, Esmann M, Nissen P, Fedosova NU. Structural insights into the high affinity binding of cardiotonic steroids to the Na+,K+-ATPase. J Struct Biol 2011;174:296-306.
17. Huliciak M, Vacek J, Sebela M, Orolinova E, Znaleziona J, Havlikova M, et al. Covalent binding of cisplatin impairs the function of Na+/K+-ATPase by binding to its cytoplasmic part. Biochem Pharmacol 2012;83:1507-13.
18. Klodos I, Esmann M, Post RL. Large-scale preparation of sodium-potassium ATPase from kidney outer medulla. Kidney Int 2002;62:2097-100.
19. Kabsch W. XDS. Acta crystallogr Sect D - Biol Crystallogr 2010;66:125-32.
20. Kabsch W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr Sect D - Biol Crystallogr 2010;66:133-44.
21. French S, Wilson K. Treatment of negative intensity observations. Acta Crystallogr Sect A 1978;34:517-25.
22. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr 2007;40:658-74.
23. Bailey S. The CCP4 suite - programs for protein crystallography. Acta Crystallogr Sect D - Biol Crystallogr 1994;50:760-3.
24. Tanley SWM, Schreurs AMM, Helliwell JR, Kroon-Batenburg LMJ. Experience with exchange and archiving of raw data: comparison of data from two diffractometers and four software packages on a series of lysozyme crystals. J Appl Crystallogr 2013;46:108-19.
25. Helliwell JR, Tanley SWM. The crystal structure analysis of the relative binding of cisplatin and carboplatin in a mixture with histidine in a protein studied at 100 and 300 K with repeated X-ray irradiation. Acta Crystallogr Sect D - Biol Crystallogr 2013; 69:121-5.
26. Banci L, Bertini I, Blazevits O, Calderone V, Cantini F, Mao JF, et al. Interaction of cisplatin with human superoxide dismutase. J Am Chem Soc 2012;134:7009-14.
27. Yamasaki K, Wang GL, Daiho T, Danko S, Suzuki H. Roles of Tyr(122)-hydrophobic cluster and K+ binding in Ca2+-releasing process of ADP-insensitive phosphoenzyme of sarcoplasmic reticulum Ca2(+)-ATPase. J Biol Chem 2008;283:29144-55.
28. Yamasaki K, Daiho T, Danko S, Suzuki H. Multiple and distinct effects of mutations of Tyr(122), Glu(123), Arg(324), and Arg(334) involved in interactions between the top part of second and fourth transmembrane helices in sarcoplasmic reticulum Ca(2+)-ATPase - changes in cytoplasmic domain organization during isometric transition of phosphoenzyme intermediate and subsequent Ca(2+) release. J Biol Chem 2004;279:2202-10.
29. Ikeda S, Mayuzumi N, Shigihara T, Epstein EH, Goldsmith LA, Ogawa H. Mutations in ATP2A2 in patients with Darier's disease. J Invest Dermatol 2003;121:475-7.
30. Miyauchi Y, Daiho T, Yamasaki K, Takahashi H, Ishida-Yamamoto A, Danko S, et al. Comprehensive analysis of expression and function of 51 sarco(endo) plasmic reticulum Ca2+-ATPase mutants associated with Darier disease. J Biol Chem 2006;281:22882-95.
31. Ma HL, Lewis D, Xu C, Inesi G, Toyoshima C. Functional and structural roles of critical amino acids within the "N", "T", and "A" domains of the Ca2+ ATPase (SERCA) headpiece. Biochemistry 2005;44:8090-100.
32. Clausen JD, Bublitz M, Arnou B, Montigny C, Jaxel C, Moller JV, et al. SERCA mutant E309Q binds two Ca2+ ions but adopts a catalytically incompetent conformation. Embo J 2013;32:3231-43.
33. Petrushanko IY, Yakushev S, Mitkevich VA, Kamanina YV, Ziganshin RH, Meng XY, et al. S-glutathionylation of the Na,K-ATPase catalytic alpha subunit is a determinant of the enzyme redox sensitivity. J Biol Chem 2012;287:32195-205.
34. Kubala M, Geletičová J, Huličiak M, Zatloukalová M, Vacek J, Šebela M. Na+/K+-ATPase inhibition by cisplatin and consequences to cisplatin nephrotoxicity. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014;158(2):194-200.